公开(公告)号：KR101311837B1

公开(公告)日：2013-09-27

申请号：KR1020110069248

申请日：2011-07-13

Applicant: 한양대학교 산학협력단 ,  서울대학교산학협력단

Inventor： 한명수 ,  이진원 ,  강윤호 ,  강수경 ,  이은선 ,  강사욱

IPC: C12N1/20 ,  A01N63/02 ,  C12R1/225

CPC classification number: Y02A20/402

Abstract: 본 발명은 특정 살조세균 또는 이를 포함하는 유해조류 제어용 조성물에 관한 것으로, 보다 구체적으로는, 락토바실러스(Lactobacillus) 속 또는 락토코커스(Lactococcus) 속 살조세균을 이용하여 유해조류 증식을 제어하는, 생물 유래의 친환경적 유해조류 제어에 관한 것으로, 특히, 락토바실러스(Lactobacillus) 속 또는 락토코커스(Lactococcus) 속 생물의 새로운 살조용도에 관한 것이다.

公开(公告)号：KR1020130009902A

公开(公告)日：2013-01-24

申请号：KR1020110069248

申请日：2011-07-13

Applicant: 한양대학교 산학협력단 ,  서울대학교산학협력단

Inventor： 한명수 ,  이진원 ,  강윤호 ,  강수경 ,  이은선 ,  강사욱

IPC: C12N1/20 ,  A01N63/02 ,  C12R1/225

CPC classification number: Y02A20/402

Abstract: PURPOSE: A composition containing a certain algicidal bacteria for controlling harmful algae is provided to suppress abnormal proliferation of the harmful algae and to prevent damage due to the harmful algae and water pollution. CONSTITUTION: Lactobacillus sp. or Lactococcus sp. algicidal bacteria are used for controlling proliferation of harmful algae. The harmful algae cause water bloom. A composition for controlling the harmful algae contains the algicidal bacteria or a material derived from the algicidal bacteria. The material derived from algicidal bacteria is prepared from a petroleum ether, diethyl ether, chloroform ethyl acetate, or N-butanol fraction of the algicidal bacteria. A method for controlling harmful algae comprises a step of treating the composition to an area where the harmful algae exist.

Abstract translation: 目的：为防止有害藻类的异常增殖，防止有害藻类和水污染造成的损害，提供含有一定杀藻细菌的组合物。 构成：乳杆菌属 或乳球菌属 杀藻细菌用于控制有害藻类的增殖。 有害藻类会引起水华。 用于控制有害藻类的组合物含有杀藻细菌或来自杀藻细菌的物质。 来自杀藻细菌的物质由石油醚，二乙醚，氯仿乙酸乙酯或杀藻细菌的N-丁醇级分制备。 控制有害藻类的方法包括将组合物处理到存在有害藻类的区域的步骤。

公开(公告)号：KR1020140076198A

公开(公告)日：2014-06-20

申请号：KR1020120144498

申请日：2012-12-12

Applicant: 서울대학교산학협력단

Inventor： 강수경

IPC: A61K35/28 ,  A61K35/15 ,  A61K8/98 ,  A61Q19/00

CPC classification number: A61K35/28 ,  A61K8/98 ,  A61K35/15 ,  A61Q19/00

Abstract: The present invention relates to a pharmaceutical composition containing an adipose tissue-derived adult stem cell extract as an active ingredient to prevent or treat dermatitis. The adult stem cell extract according to the present invention is particularly effective in relieving inflammation by reducing inflammatory factors in epidermis of a lesion and increasing immune regulatory factors, and improves clinical indices of atopic dermatitis, thereby being useful as an active ingredient of a composition for preventing and treating the atopic dermatitis.

Abstract translation: 本发明涉及含有脂肪组织来源的成体干细胞提取物作为预防或治疗皮炎的活性成分的药物组合物。 根据本发明的成体干细胞提取物通过减少损伤表皮中的炎症因子和增加免疫调节因子来减轻炎症是特别有效的，并改善特应性皮炎的临床指标，从而可用作组合物的活性成分 预防和治疗特应性皮炎。

公开(公告)号：KR101087614B1

公开(公告)日：2011-11-29

申请号：KR1020080138725

申请日：2008-12-31

Applicant: 서울대학교산학협력단

Inventor： 강수경

IPC: A61K31/7105 ,  A61P35/00

CPC classification number: A61K31/7105

Abstract: 본 발명은 BCNU(1,3-Bis(2-chloroethyl)-1-nitrosourea, Carmustine)-내성 다형성 교모세포종 치료용 약학적 조성물에 관한 것으로, 구체적으로 줄기세포 마커인 Rex-1(
r educed
ex pression-1)의 발현을 억제하는 상기 Rex-1에 특이적인 siRNA를 유효성분으로 포함함으로써 BCNU-내성 다형성 교모세포종의 세포사멸 및 종양성장 억제를 유도하는 약학적 조성물에 관한 것이다. 본 발명의 약학적 조성물은 상기 BCNU와 병용투여함으로써 BCNU-내성 다형성 교모세포종의 치료에 유용하게 이용될 수 있다.
BCNU-내성 다형성 교모세포종, Rex-1, siRNA

公开(公告)号：KR1020130026950A

公开(公告)日：2013-03-14

申请号：KR1020110090424

申请日：2011-09-06

Applicant: 서울대학교산학협력단

Inventor： 강수경

IPC: A61K48/00 ,  A61K31/7088 ,  A61K31/7105 ,  A61P25/00

CPC classification number: C12N15/113 ,  C12N2310/113

Abstract: PURPOSE: A pharmaceutical composition containing an miRNA expression inhibitor for preventing and treating nervous system disorders is provided to treat spinal cord injury. CONSTITUTION: A pharmaceutical composition for preventing and treating nervous system disorders contains an miRNA expression inhibitor as an active ingredient. The miR486 expression inhibitor is selected from the group consisting of an antisense oligonucleotide, siRNA, shRNA, and ribozyme which complementarily bind to miR486 gene. The miR486 expression inhibitor enhances NeuroD6 expression.

Abstract translation: 目的：提供含有miRNA表达抑制剂用于预防和治疗神经系统疾病的药物组合物，用于治疗脊髓损伤。 构成：用于预防和治疗神经系统疾病的药物组合物含有miRNA表达抑制剂作为活性成分。 miR486表达抑制剂选自与miR486基因互补结合的反义寡核苷酸，siRNA，shRNA和核酶。 miR486表达抑制剂增强NeuroD6表达。

公开(公告)号：KR1020120002134A

公开(公告)日：2012-01-05

申请号：KR1020100062868

申请日：2010-06-30

Applicant: 서울대학교산학협력단

Inventor： 강수경

IPC: A61K31/121 ,  A61K31/12 ,  C12N5/0775 ,  C12N5/02

CPC classification number: A61K35/35 ,  C12N5/0667 ,  C12N5/0696 ,  C12N2500/02 ,  C12N2500/74 ,  C12N2501/999 ,  C12N2506/1384

Abstract: PURPOSE: A dedifferentitaion of adipose tissue stromal cells(ATSC) is provided to regenerate neuron and to enhance blood glucose. CONSTITUTION: A dedifferentiation of adipose tissue stromal cells(ATSC) into pluripotent stem cells contains 4-(3, 4-Dihydroxy-phenyl)-derivative(DHP-derivative) or pharmaceutically acceptable salt thereof as an active ingredient. The DHP-derivative is denoted by chemical formula 1 or 2. A method for inducing dedifferentiation of ATSC comprises: a step of culturing the ATSC; a step of culturing the cultured ATSCs in a medium containing the DHP-derivative or pharmaceutically acceptable salt thereof under a hypoxic condition; and a step of culturing under dedifferentiated ATSC culture condition.

Abstract translation: 目的：提供脂肪组织基质细胞（ATSC）的去分化以再生神经元并增强血糖。 构成：将脂肪组织基质细胞（ATSC）去分化成多能干细胞含有4-（3,4-二羟基 - 苯基）衍生物（DHP衍生物）或其药学上可接受的盐作为活性成分。 DHP衍生物由化学式1或2表示。诱导ATSC去分化的方法包括：培养ATSC的步骤; 在含有DHP衍生物或其药学上可接受的盐的培养基中在缺氧条件下培养培养的ATSC的步骤; 和在分化ATSC培养条件下培养的步骤。

公开(公告)号：KR1020100080098A

公开(公告)日：2010-07-08

申请号：KR1020080138725

申请日：2008-12-31

Applicant: 서울대학교산학협력단

Inventor： 강수경

IPC: A61K31/7105 ,  A61P35/00

CPC classification number: A61K31/7105

Abstract: PURPOSE: A pharmaceutical composition for treating BCNU(1,3-Bis(2-chloroethyl)-1-nitrosourea, Carmustine)-resitance gliobalstoma multiforme is provided to suppress Rex-1 expression. CONSTITUTION: A pharmaceutical composition for treating BCNU-resistance glioblastoma multiforme contains siRNA as an active ingredient, which is specific to target sequence of Rex-1. The target sequence of Rex-1 is sequence number 17 or 18. A pharmaceutical composition for treating BCNU-resistance glioblastoma multiforme contains the siRNA which is specific to the target sequence of Rex-1 and BCNU as an active ingredient.

Abstract translation: 目的：提供一种用于治疗BCNU（1,3-双（2-氯乙基）-1-亚硝基脲，卡莫司汀） - 多形性遗传性胶质瘤的药物组合物，以抑制Rex-1表达。 构成：用于治疗BCNU抗性胶质母细胞瘤多形性的药物组合物含有siRNA作为活性成分，其特异于Rex-1的靶序列。 Rex-1的靶序列是序列号17或18.用于治疗BCNU耐药性多形性胶质母细胞瘤的药物组合物含有对Rex-1和BCNU的靶序列特异的siRNA作为活性成分。

公开(公告)号：KR101346582B1

公开(公告)日：2013-12-30

申请号：KR1020110115861

申请日：2011-11-08

Applicant: 서울대학교산학협력단

Inventor： 강수경

IPC: C12N5/0793 ,  A61K31/381 ,  A61K35/28

CPC classification number: A61K31/381 ,  A61K35/28 ,  A61K35/30 ,  A61K2300/00

Abstract: 본 발명은 지방조직유래줄기세포에 CBM-1078을 처리함으로써 분화 유도된 GABA성 신경세포를 유효성분으로 포함하는 신경성 통증 예방 및 치료용 약학적 조성물에 관한 것으로, 구체적으로, 본 발명의 ATSCs에 CBM-1078을 처리함으로써 분화유도된 GABA성 신경세포를 신경성 통증 동물에 이식하였을 때, 신경보호적 및 신경재생 기능적 역할을 확인하였으므로, 이를 유효성분으로 포함하는 신경성 통증 예방 및 치료용 약학적 조성물로 이용할 수 있다.

公开(公告)号：KR1020130050663A

公开(公告)日：2013-05-16

申请号：KR1020110115861

申请日：2011-11-08

Applicant: 서울대학교산학협력단

Inventor： 강수경

IPC: C12N5/0793 ,  A61K31/381 ,  A61K35/28

CPC classification number: A61K31/381 ,  A61K35/28 ,  A61K35/30 ,  A61K2300/00 ,  C12N5/0619 ,  C12N2506/1384

Abstract: PURPOSE: A pharmaceutical composition containing GABAergic neurons which is differentiated by treating adipose-derived stem cells with CBM-1078 for preventing and treating neuropathic pain is provided to protect neurons, and to regenerates nerves. CONSTITUTION: A method for differentiating adult stem cells to GABAergic neurons comprises a step of culturing the adult stem cells in a differentiation medium containing a low molecular compound. The low molecular compound induces neurons, and is CBM-1078. The adult stem cells are derived from adipose. The concentration of the low molecular compound is 0.2-5 nM.

Abstract translation: 目的：提供含有GABA能神经元的药物组合物，其通过用CBM-1078处理脂肪来源的干细胞用于预防和治疗神经性疼痛来分化，以保护神经元并再生神经。 构成：将成体干细胞分化为GABA能神经元的方法包括在含有低分子化合物的分化培养基中培养成体干细胞的步骤。 低分子化合物诱导神经元，是CBM-1078。 成体干细胞来源于脂肪。 低分子化合物的浓度为0.2-5nM。

公开(公告)号：KR1020130026949A

公开(公告)日：2013-03-14

申请号：KR1020110090423

申请日：2011-09-06

Applicant: 서울대학교산학협력단 ,  주식회사 강스템바이오텍

Inventor： 강수경

IPC: A61K48/00 ,  A61K31/7105 ,  A61K31/7088 ,  A61P25/00

CPC classification number: A61K48/00 ,  G01N33/5008

Abstract: PURPOSE: A pharmaceutical composition containing miR23b for preventing and treating neuropathic pain is provided to suppress NOX4 expression. CONSTITUTION: A pharmaceutical composition for preventing and treating neuropathic pain contains miR23b as an active ingredient. The miR23b suppresses NOX4 expression and enhances GABA expression. The pharmaceutical composition contains a NOX4 inhibitor. The NOX4 inhibitor is siRNA or antisense nucleotide of NOX4 gene or an antibody which is specific to NOX4 protein.

Abstract translation: 目的：提供含有预防和治疗神经性疼痛的miR23b的药物组合物，以抑制NOX4的表达。 构成：用于预防和治疗神经性疼痛的药物组合物含有miR23b作为活性成分。 miR23b抑制NOX4表达并增强GABA表达。 药物组合物含有NOX4抑制剂。 NOX4抑制剂是NOX4基因的siRNA或反义核苷酸或对NOX4蛋白特异的抗体。